AgraFlora (OTCMKTS:AGFAF) Finalizing Process Of manufacturing Licence For Edibles Facility Enters Distribution Agreement In Germany

AgraFlora Organics International Inc. (OTCMKTS:AGFAF) has submitted an official response to the first Request for More Information from Health Canada about a Standard Processing Licensing application. The application is for the company’s 51,000 sq. ft. fully automated manufacturing facility for edibles in Winnipeg, Manitoba.

AgraFlora a step away from a manufacturing license for edibles facility

The response for the RMI is a big step in the process of receiving Standard Processing Licenses for the edibles manufacturing facility. In late May, the company submitted the site evidence package to the regulator for a manufacturing license. On August 27, 2020, AgraFlora launched R&D trials through its Health Canada R&D license for dialing in formulations for marijuana activated gelatine and pectin gummies, sugar-free variants, and hard candy. The company is currently in discussions with various companies in Canada regarding the formulation and product development as an R & D service. The company is optimistic the R&D services deals will be vital in the long-term production pathway.

James Fletcher, the Operational Manager and Co-founder of EIC, stated that receiving a manufacturing license for the edibles manufacturing facility is a huge milestone for AgraFlora. He added that the company has finalized the RMI request submission, which puts the company a step closer to receiving a Manufacturing License for the edibles facility to commence commercial operations. Fletcher said that the R&D trials have helped the company with strong results for recipes with favorable texture, flavor, and manufacturing efficiencies.

AgroFlora’s subsidiary to distribute cannabis products in Germany

Recently AgraFlora announced that on September 9, 2020, its wholly-owned subsidiary Farmako GmbH entered a distribution agreement with IM Cannabis Corp’s German subsidiary Adjupharm GmbH. According to the terms of the agreement, Farmako will receive EU-GMP medical cannabis from Adjupharm for distribution across Germany to medical cannabis users for 3 years. The AgraFlora subsidiary will carry the distribution in Germany under the IM brand to Germany Pharmacies.

The products form Adjupharm, which Farmako will distribute, include high potency THC flower with the portfolio expected to be enhanced in Q1 2021.

Related Posts

About The Author

Add Comment